IMR Press / FBL / Volume 28 / Issue 2 / DOI: 10.31083/j.fbl2802032
Open Access Review
Molecular Linkage under the Bicuspid Aortic Valve with Dyslipidemia
Show Less
1 Department of Cardiology, The Xiamen Cardiovascular Hospital of Xiamen University, 361005 Xiamen, Fujian, China
*Correspondence: (Ye Cheng); (Xin Su)
Front. Biosci. (Landmark Ed) 2023, 28(2), 32;
Submitted: 6 September 2022 | Revised: 18 November 2022 | Accepted: 21 November 2022 | Published: 22 February 2023
(This article belongs to the Special Issue Advances in Endocrinology)
Copyright: © 2023 The Author(s). Published by IMR Press.

This is an open access article under the CC BY 4.0 license.


Dyslipidemia is correlated with diverse cardiovascular problems, such as obesity, hypertension, and atherosclerosis, which are summarized as metabolic syndrome. Bicuspid aortic valve (BAV), as one of the congenital heart defects, is shown to influence approximately 2.2% of the general population worldwide, inducing the severe pathological development of aortic valve stenosis (AVS) or aortic valve regurgitation (AVR), and also to aortic dilatation. Notably, emerging evidence showed that BAV was correlated with not only the aortic valve and wall diseases but also the dyslipidemic related cardiovascular disorders. Recent results also proposed that multiple potential molecular mechanisms inducing the progression of dyslipidemia played important roles in BAV and the progression of AVS. Several altered serum biomarkers under dyslipidemic condition, including higher low-density lipoprotein cholesterol (LDL-C), higher lipoprotein (a) [Lp(a)], lower high-density lipoprotein cholesterol (HDL-C), and different pro-inflammatory signaling pathways, have proposed to embrace a vital function in the development of BAV correlated cardiovascular diseases. In this review, different molecular mechanisms which embrace an important role in personalized prognosis in the subjects with BAV was summarized. The illustration of those mechanisms might facilitate an accurate follow-up for patients with BAV and give new pharmacological strategies to improve development of dyslipidemia and BAV.

bicuspid aortic valve
aortic valve stenosis
aortic valve regurgitation
inflammatory pathways
2020Y2016/Fujian Clinical Medical Research Center of Cardiovascular Interventional Diagnosis and Treatment
81900365/National Natural Science Foundation of China
Back to top